文献速递浆细胞疾病造血干细胞移植与细胞治疗

阻断膜抗原的蛋白酶体降解可增强CAR-T细胞疗效

Boosting CAR T-cell efficacy by blocking proteasomal degradation of membrane antigens.
PubMed 文献 · Blood · 2026-01-01

本研究鉴定BCMA为经质膜K48连接多泛素化后由p97依赖的泛素-蛋白酶体系统降解的短寿命蛋白,蛋白酶体抑制剂卡非佐米可增强BCMA表达及BCMA CAR-T细胞对敏感和难治MM细胞的疗效;10例BCMA CAR-T后复发患者经卡非佐米治疗后BCMA表达均升高,但临床反应仅见于有残留和/或扩增CAR-T细胞者。

要点

  • BCMA在质膜发生K48连接多泛素化,经p97依赖的泛素-蛋白酶体系统降解。
  • 卡非佐米可增强BCMA表达及BCMA CAR-T细胞对蛋白酶体抑制剂敏感和难治MM细胞的疗效。
  • 10例BCMA CAR-T后复发患者经卡非佐米治疗后BCMA表达均升高,临床反应仅见于有残留和/或扩增CAR-T细胞者。

核心结论

  • BCMA经质膜K48连接多泛素化后由p97依赖的泛素-蛋白酶体系统降解,卡非佐米可增强BCMA表达并增强BCMA CAR-T细胞疗效。

研究设计与样本

  • 研究包括体外和体内实验,以及10例接受BCMA CAR-T细胞治疗后复发患者按CFZ after BCMA CAR-T cell(CarCAR)方案接受卡非佐米治疗的观察。

主要发现

  • BCMA是高度短寿命蛋白,在质膜发生K48连接多泛素化,经p97依赖的泛素-蛋白酶体系统降解。
  • 临床获批的蛋白酶体抑制剂卡非佐米在体外和体内显著增强BCMA导向CAR-T细胞对蛋白酶体抑制剂敏感和难治MM细胞的疗效。
  • 10例BCMA CAR-T细胞治疗后复发患者接受卡非佐米治疗后,所有患者BCMA表达均升高。
  • 临床反应仅见于有残留和/或扩增CAR-T细胞的患者,提示CAR-T细胞功能恢复。

关键数值与推荐

  • 10例BCMA CAR-T细胞治疗后复发患者接受卡非佐米治疗后,所有患者BCMA表达均升高。

临床怎么用

  • 作者认为这些发现为BCMA CAR-T细胞治疗后复发或难治MM使用卡非佐米治疗提供了依据。
  • 作者倡导未来开展卡非佐米联合BCMA CAR-T细胞的试验。
  • 作者认为这些发现为探索其他免疫治疗抗原的泛素-蛋白酶体系统依赖性降解提供了框架。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Chimeric antigen receptor (CAR) T cells exhibit high response rates in B-cell malignancies, but most patients eventually relapse. A key mechanism of treatment failure is the loss or downregulation of tumor antigen expression, yet strategies to modulate cell surface levels of CAR T-cell targets remain largely unexplored. Here, we identify B-cell maturation antigen (BCMA), a central CAR T-cell target in multiple myeloma (MM), as a highly short-lived protein that undergoes K48-linked polyubiquitylation at the plasma membrane, leading to its p97-dependent degradation via the ubiquitin-proteasome system (UPS). This previously unprecedented mechanism of plasma membrane protein regulation enables significant enhancement of BCMA expression via proteasome inhibitors (PIs). The clinically approved PI carfilzomib (CFZ) significantly enhances the efficacy of BCMA-directed CAR T cells against both PI-sensitive and -refractory MM cells in vitro and in vivo. Notably, CFZ treatment of 10 patients with BMCA CAR T-cell therapy relapse, under the CFZ after BCMA CAR T-cell (CarCAR) protocol, resulted in increased BCMA expression in all patients. However, clinical responses were observed only in those with residual and/or expanding CAR T cells, suggesting restored CAR T-cell function. These findings provide a rationale for the use of CFZ treatment in relapsed or refractory MM after BCMA CAR T-cell therapy, advocate for future trials combining CFZ with BCMA CAR T cells, and provide a framework for exploring UPS-dependent degradation of other immunotherapy antigens.

来源:Blood,查看原文。版权归原作者所有。

引用

  1. Rieger L, Irlinger K, Füchsl F, et al. Boosting CAR T-cell efficacy by blocking proteasomal degradation of membrane antigens. Blood. 2026. PMID: 40638685. doi:10.1182/blood.2024027616

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。